Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
Jingjun Huang,Wensou Huang,Meixiao Zhan,Yongjian Guo,Licong Liang,Mingyue Cai,Liteng Lin,Mingji He,Hui Lian,Ligong Lu,Kangshun Zhu
DOI: https://doi.org/10.2147/JHC.S339379
2022-01-19
Journal of Hepatocellular Carcinoma
Abstract:Jingjun Huang, 1, &ast Wensou Huang, 1, &ast Meixiao Zhan, 2, &ast Yongjian Guo, 1 Licong Liang, 1 Mingyue Cai, 1 Liteng Lin, 1 Mingji He, 3 Hui Lian, 3 Ligong Lu, 2 Kangshun Zhu 1 1 Department of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China; 2 Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai City, Guangdong Province, People's Republic of China; 3 Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kangshun Zhu Department of Interventional Radiology, Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Road, Guangzhou City, Guangdong, 510260, People's Republic of China Tel +86-20-34156205 Fax +86-20-34153709 Email Ligong Lu Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, 79 Kangning Road, Zhuhai City, Guangdong Province, 519000, People's Republic of China Tel +86 7-56-2222569 Fax +86 7-56-2162086 Email lu_lig Purpose: To evaluate the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with oxaliplatin plus fluorouracil and leucovorin (FOLFOX)-based hepatic arterial infusion chemotherapy (D-TACE-HAIC) for unresectable large (5.1– 10 cm) or huge (> 10 cm) hepatocellular carcinoma (HCC). Methods: This retrospective study evaluated consecutive patients with unresectable large or huge HCC who underwent D-TACE-HAIC (D-TACE-HAIC group) or DEB-TACE (DEB-TACE group) from January 2017 to December 2020. At imaging, tumor infiltrating appearance was classified into smooth tumor margin, non-smooth tumor margin, and macrovascular invasion. Adverse events, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between the two groups. Results: A total of 133 patients (mean age, 53 years ± 12; 117 men) were included: 69 underwent D-TACE-HAIC and 64 underwent DEB-TACE. The patients who underwent D-TACE-HAIC had higher ORR (71.0% vs 53.1%; P = 0.033), longer PFS (median, 9.3 vs 6.3 months; P = 0.005), and better OS (median, 19.0 vs 14.0 months; P = 0.008) than those who underwent DEB-TACE. In subgroup analysis, patients with non-smooth tumor margin (median, 20.8 vs 13.0 months; P = 0.031) or macrovascular invasion (median, 15.0 vs 11.0 months; P = 0.015) had significantly longer OS in D-TACE-HAIC group than in DEB-TACE group; but in patients with smooth tumor margin, OS between the two groups was similar (median, 37.0 vs 35.0 months; P = 0.458). DEB-TACE, non-smooth tumor margin, and macrovascular invasion were independent prognostic factors for poor OS in uni- and multivariable analyses. The incidence of grade 3/4 adverse events was not statistically different between the two groups (37.7% vs 28.1%; P = 0.242). Conclusion: D-TACE-HAIC was tolerable and led to better OS than DEB-TACE in patients with large or huge HCC, especially in those with non-smooth tumor margin or macrovascular invasion. Keywords: liver cancer, high tumor burden, chemoembolization, drug-eluting beads, hepatic arterial infusion chemotherapy, survival analysis The management of hepatocellular carcinomas (HCC) in patients with large (5.1–10 cm in diameter) or huge (>10 cm in diameter) tumors who are not candidates for surgical resection remains a major challenge. 1 The large or huge HCC was usually unresectable due to insufficient surgical margin, a residual liver volume estimated less than 30% after resection, or macrovascular invasion. 2 The efficacy of conventional transarterial chemoembolization (c-TACE) using lipiodol mixed with chemotherapeutics on large or huge HCC is very limited, with poor objective response rate (ORR) of 16–29% 3,4 and overall survival (OS) of only 6.5–9.1 months. 4,5 Different from c-TACE, TACE using drug-eluting beads (DEB-TACE) can increase the intensity and duration of tumor ischemic necrosis and deliver large amounts of chemotherapeutics to the tumor in a controlled and sustained manner. 6,7 For large or -Abstract Truncated-
oncology